We have previously reported that histone deacetylase (HDAC) inhibitors dramatically enhanced IL‐13Rα2 expression in receptor‐negative pancreatic cancer cells and in addition, HDAC inhibitors enhanced expression of IL‐13Rα2 in IL‐13Rα2 positive tumours.59 The gene discussed is HDAC9; the disease is neoplasm.